VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of$ 0.50. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8%. A quarter ago, it was expected that this company would post a loss of$ 0.40 per share when it actually produced a loss of $0.42, delivering a surprise of -5%.Over the last four quarters, the company has sur ...